All News
Don’t miss the “window of opportunity” for aggressive treatment in early RA!
with active RA, risk of ILD 6x and RA-related lung disease 4x higher
#ACR24 @RheumNow ABST#0802 https://t.co/yxlfInte6A
Jiha Lee JihaRheum ( View Tweet)
Harkins @DrTrishHarkins et al. 1 year outcomes of 65 PMR patients treated in FTC. 32.7% experienced relapse, 28% still on GCs, 21% on tocilizumab. @RheumNow #ACR24 Abstr#0739 https://t.co/uYBYhPqGQE https://t.co/n9x9BDTPKg
Links:
Richard Conway RichardPAConway ( View Tweet)
#Disparites posters #ACR24 - Analyzed 954 SLE patients
- Black and Asian patients had higher severe damage events
- Neighborhood disadvantage (ADI) linked to increased severe damage
- Older age and comorbidities increased damage risk
abst#0362 @rhuemnow
Bella Mehta bella_mehta ( View Tweet)
Disparities posters #ACR24
- Analyzed 10,604 SLE patients
- 18.7% in the lowest SES group experienced functional status decline vs. 12.5% in the highest SES group
- African American patients and Greater neighborhood deprivation did worse
#ACR24 abst#0190
@RheumNow
Bella Mehta bella_mehta ( View Tweet)
More steroid-sparing options for #IgG4RD!
Abstract 0775: In pts w/ IgG4:
- Inebilizumab (CD19-monoclonal ab) vs placebo associated with reduced risk of flare (HR 0.13; 95% CI 0.06, 0.28)
AEs: infections, infusion reactions, lymphopenia
#ACR24 @RheumNow https://t.co/Vr5hcd2E7E
Akhil Sood MD AkhilSoodMD ( View Tweet)
McDermott @jeffsparks et al. SAIL-RA prospective study. 172 early RA patients. RA lund disease in 16%, RA-ILD in 11%. Disease activity strongest predictor RA lung disease, HR 4.89, and RA-ILD, HR 6.17. @RheumNow #ACR24 Abstr#0802 #ACRbest https://t.co/ia0koG64mL https://t.co/U1KdgcUfOy
Links:
Richard Conway RichardPAConway ( View Tweet)
The 2009 ASAS classification criteria did not meet the set targets of 75% sensitivity and 90% specificity in the CLASSIC cohort, indicating the need for revision of these criteria to increase its performance and validity in classification of axSpA.
Abst#0820 #ACR24 #ACRBest… https://t.co/lF3QbRUpx3 https://t.co/SHPMpCjizS
Links:
Adela Castro AdelaCastro222 ( View Tweet)
This interesting systematic review showed that the prevalence of ILD was 15% in patients with SLE. This higher than previously reported! #ACR24 @RheumNow https://t.co/O1aZUUL4Ho
Gabriela Martinez Zayas, MD MartinezZayasMd ( View Tweet)
Researchers developed a digital messaging program to reduce fatigue in SLE
- Grounded in social cognitive and self-determination theories
- Reviewed 148 messages, refined based on patient feedback
- High patient ratings, future will see more of these #ACR24 abst#0362 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
#ACR24 abst#0430
- Analyzed 61 SLE pregnancies
- Higher early gestational Mean Arterial Pressure before 20 Weeks linked to increased preeclampsia risk
- MAP trends at 8-10 and 17-19 weeks showed highest predictive accuracy for risk prediction
@RheumNow https://t.co/37mg0WX43v
Bella Mehta bella_mehta ( View Tweet)
Global meta-analysis of 61 studies shows TB Preventive treatment (TPT)
- Reduces active TB risk in rheumatic disease patients by 29% (RR: 0.71, CI: 0.57–0.87)
- Best outcomes in high TB-burden countries (RR: 0.51) and with isoniazid for >9 months (RR: 0.52).
- Dual screening… https://t.co/4P1982ngvL
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Ab#0458 #ACR24
10 year outcomes of 176 patients with seroneg RA
32 pts (18%) had change in dx - SpA (11), seropos RA (6), OA (5), crystal (3), CTD (3), Ifn-related/paraneopl/RS3PE, sarcoid (1)
40 (23%) had drug-free remission
30 (17%) started b/tsDMARD
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Gender differences in axSpA extend to dse activity assessment tools.
PREDICT-SpA:
🔶️BASDAI score performed better in women.
🔶️ ASDAS-CRP homogenous performance on both genders.
Consider BASDAI for assessing dse activity in women?
@RheumNow #ACR24 abs571
@rheumarhyme https://t.co/rKJXn2EPXa
sheila RHEUMarampa ( View Tweet)
👴🏼 Ageing & RMDs at #ACR24
🧠 14 factors associated with dementia
❗️Justin Levenson tells us that if we could address all of these, we could reduce dementia risk by 45%!
@RheumNow https://t.co/SgC5KMohXy
Mrinalini Dey DrMiniDey ( View Tweet)
Study on socioeconomic factors in SLE hospitalizations - US wide data
- No insurance & non-metro areas linked to shorter LOS, lower costs, higher mortality
- Higher income & age increase charges
- Targeted interventions needed to improve outcomes
#ACR24 abst#0615 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Can we predict who will develop #RA-#ILD?
Wheeler et al showed a combination of genetic risk score, peripheral protein #biomarkers & clinical risk factors can help identify RA-ILD in RA patients.
Does this bring us closer to #PersonalisedMedicine?
Ab0799 #ACR24 @RheumNow https://t.co/JZkJNGmLM1
Mrinalini Dey DrMiniDey ( View Tweet)
Study on pregnancy outcome disparities in SLE:
- Analyzed 685 women, 1888 pregnancies
- Pre-SLE state linked to fewer live births, higher preeclampsia risk
- Outcomes worse post-SLE diagnosis
#ACR24 abst#0440 @RheumNow https://t.co/NpEYQZ73uo
Links:
Bella Mehta bella_mehta ( View Tweet)
A study from the EuroSpA collaboration validates new BASDAI cut-offs for disease activity in axial spondyloarthritis based in ASDAS: <1.4 for remission, <2.8 for low activity, and >5.9 for very high activity. This research enhances our understanding of disease states and their… https://t.co/OkPiTwSHz6 https://t.co/NjIDeme9dm
Links:
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Ok so trivial tweet here but I just love the name of this outcome measure... "LFA-REAL" 😄😆
Serious topic though; PRO's are huge in SLE research!
@RheumNow #ACR24 Abstr#0626 https://t.co/w34zTNjSbH
Mike Putman EBRheum ( View Tweet)
#0600
🔬BKZ achieves sustained impact in PsA
➡️ BE OPTIMAL & BE COMPLETE trials:BKZ 160 mg Q4W bDMARD-naïve & TNFi-IR PsA pts
➡️Pain,function,fatigue & skin showed greatest & sustained reductions @ 2 yrs👇
🎯BKZ offers sustained response in 🔑PsA domains
#ACR24 @RheumNow https://t.co/uhzZoOrr3H
Caoilfhionn Connolly CaoilfhionnMD ( View Tweet)
